Last reviewed · How we verify

Cttq — Portfolio Competitive Intelligence Brief

Cttq pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Original Zoledronic Acid Original Zoledronic Acid marketed
Generic Zoledronic Acid Generic Zoledronic Acid marketed Bisphosphonate Farnesyl pyrophosphate synthase Oncology, Bone Metabolism

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AUVA Traumazentrum Vienna Site UKH Meidling · 1 shared drug class
  2. Aarhus University Hospital · 1 shared drug class
  3. Amgen · 1 shared drug class
  4. Axsome Therapeutics, Inc. · 1 shared drug class
  5. Chinese Society of Lung Cancer · 1 shared drug class
  6. Chinese University of Hong Kong · 1 shared drug class
  7. Daiichi Sankyo Co., Ltd. · 1 shared drug class
  8. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cttq:

Cite this brief

Drug Landscape (2026). Cttq — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cttq. Accessed 2026-05-14.

Related